



US 20130180016A1

(19) **United States**(12) **Patent Application Publication**
Narva et al.(10) **Pub. No.: US 2013/0180016 A1**(43) **Pub. Date: Jul. 11, 2013**(54) **COMBINATIONS INCLUDING
CRY34AB/35AB AND CRY3BA PROTEINS TO
PREVENT DEVELOPMENT OF RESISTANCE
IN CORN ROOTWORMS (DIABROTICA SPP.)**(75) Inventors: **Kenneth Narva**, Zionsville, IN (US);
Thomas Meade, Zionsville, IN (US);
Kristin Fencil, San Diego, CA (US);
Huarong Li, Zionsville, IN (US);
Timothy D. Hey, Zionsville, IN (US);
Aaron T. Woosley, Fishers, IN (US);
Monica B. Olson, Lebanon, IN (US)(73) Assignee: **DOW AGROSCIENCES LLC**,
Indianapolis, IN (US)(21) Appl. No.: **13/643,048**(22) PCT Filed: **Apr. 22, 2011**(86) PCT No.: **PCT/US11/33618**

§ 371 (c)(1),

(2), (4) Date: **Mar. 6, 2013****Related U.S. Application Data**

(60) Provisional application No. 61/477,447, filed on Apr. 20, 2011, provisional application No. 61/476,005, filed on Apr. 15, 2011, provisional application No. 61/388,273, filed on Sep. 30, 2010, provisional application No. 61/327,240, filed on Apr. 23, 2010.

Publication Classification(51) **Int. Cl.****A01N 43/50** (2006.01)**A01H 5/10** (2006.01)(52) **U.S. Cl.**CPC . **A01N 43/50** (2013.01); **A01H 5/10** (2013.01)USPC **800/302**; 435/419; 514/4.5; 435/468

(57)

ABSTRACT

The subject invention relates in part to Cry34Ab/35Ab in combination with Cry3Ba. The subject invention relates in part to the surprising discovery that Cry34Ab/Cry35Ab and Cry3Ba are useful for preventing development of resistance (to either insecticidal protein system alone) by a corn rootworm (*Diabrotica* spp.) population. As one skilled in the art will recognize with the benefit of this disclosure, plants producing these insecticidal Cry proteins will be useful to mitigate concern that a corn rootworm population could develop that would be resistant to either of these insecticidal protein systems alone. The subject invention is supported in part by the discovery that components of these Cry protein systems do not compete with each other for binding corn rootworm gut receptors. The subject invention also relates in part to triple stacks or "pyramids" of three (or more) toxin systems, with Cry34Ab/Cry35Ab and Cry3Ba being the base pair. Thus, plants (and acreage planted with such plants) that produce these two insecticidal protein systems are included within the scope of the subject invention.




Figure 1. Binding of ^{125}I -Cry35Ab1 (**A**) and ^{125}I -Cry3Ba1 (**B**) as a function of input radiolabeled Cry toxins (nM) to BBMVs at 0.1 mg/ml prepared from western corn rootworm larvae. Specific binding = total binding — non-specific binding, error bar = SEM (standard error of mean). Cry35Ab1: chymotrypsinized core (40 kDa); and Cry3Ba1: trypsinized core (55 kDa).




Figure 2. Binding of ^{125}I -Cry35Ab1 at the presence of Cry34Ab1 (1:50 = ^{125}I -Cry35Ab1:Cry34Ab1, molar ratio) as a function of input radiolabeled Cry35Ab1 (nM) to BBMVs at 0.03 mg/ml prepared from western corn rootworm larvae. Specific binding = total binding — non-specific binding, error bar = SEM (standard error of mean). Cry35Ab1: chymotrypsinized core (40 kDa)




Figure 3. Percentage of initial specific binding of ^{125}I -Cry35Ab1 to BBMVs at 0.1 mg/ml (Panel A) or at 0.03 mg/ml (Panel B) prepared from western corn rootworm larvae at different concentrations of non-labeled competitors incubated with 5 nM ^{125}I -Cry35Ab1 alone (Panel A) or with 250 nM Cry34Ab1+5 nM ^{125}I -Cry35Ab1 (Panel B). Cry34Ab1: full length (14 kDa); Cry35Ab1: chymotrypsinized core (40 kDa); and Cry3Ba1: trypsinized core (55 kDa); log 0.1=-1.0, log 1=0, log10=1.0, log100=2.0, log1,000=3.0




Figure 4. Percentage of initial total binding of ^{125}I -Cry3Ba1 to BBMVs at 0.1 mg/ml prepared from western corn rootworm larvae at different concentrations of non-labeled competitors incubated with 5 nM ^{125}I -Cry3Ba1. Cry34Ab1: full length (14 kDa); Cry35Ab1: chymotrypsinized core (40 kDa); and Cry3Ba1: trypsinized core (55 kDa); log 0.1=-1.0, log 1=0, log 10=1.0, log 100=2.0, log 1,000=3.0

**COMBINATIONS INCLUDING
CRY34AB/35AB AND CRY3BA PROTEINS TO
PREVENT DEVELOPMENT OF RESISTANCE
IN CORN ROOTWORMS (DIABROTICA SPP.)**

BACKGROUND

[0001] Humans grow corn for food and energy applications. Corn is an important crop. It is an important source of food, food products, and animal feed in many areas of the world. Insects eat and damage plants and thereby undermine these human efforts. Billions of dollars are spent each year to control insect pests and additional billions are lost to the damage they inflict.

[0002] Damage caused by insect pests is a major factor in the loss of the world's corn crops, despite the use of protective measures such as chemical pesticides. In view of this, insect resistance has been genetically engineered into crops such as corn in order to control insect damage and to reduce the need for traditional chemical pesticides.

[0003] Over 10 million acres of U.S. corn are infested with corn rootworm species complex each year. The corn rootworm species complex includes the northern corn rootworm (*Diabrotica barberi*), the southern corn rootworm (*D. undecimpunctata howardi*), and the western corn rootworm (*D. virgifera virgifera*). (Other species include *Diabrotica virgifera zea* (Mexican corn rootworm), *Diabrotica balteata* (Brazilian corn rootworm), and Brazilian corn rootworm complex (*Diabrotica viridula* and *Diabrotica speciosa*).)

[0004] The soil-dwelling larvae of these *Diabrotica* species feed on the root of the corn plant, causing lodging. Lodging eventually reduces corn yield and often results in death of the plant. By feeding on cornsilks, the adult beetles reduce pollination and, therefore, detrimentally affect the yield of corn per plant. In addition, adults and larvae of the genus *Diabrotica* attack cucurbit crops (cucumbers, melons, squash, etc.) and many vegetable and field crops in commercial production as well as those being grown in home gardens.

[0005] Synthetic organic chemical insecticides have been the primary tools used to control insect pests but biological insecticides, such as the insecticidal proteins derived from *Bacillus thuringiensis* (Bt), have played an important role in some areas. The ability to produce insect-resistant plants through transformation with Bt insecticidal protein genes has revolutionized modern agriculture and heightened the importance and value of insecticidal proteins and their genes.

[0006] Insecticidal crystal proteins from some strains of *Bacillus thuringiensis* (B.t.) are well-known in the art. See, e.g., Hofte et al., *Microbial Reviews*, Vol. 53, No. 2, pp. 242-255 (1989). These proteins are typically produced by the bacteria as approximately 130 kDa protoxins that are then cleaved by proteases in the insect midgut, after ingestion by the insect, to yield a roughly 60 kDa core toxin. These proteins are known as crystal proteins because distinct crystalline inclusions can be observed with spores in some strains of B.t. These crystalline inclusions are often composed of several distinct proteins.

[0007] One group of genes which have been utilized for the production of transgenic insect resistant crops are the delta-endotoxins from *Bacillus thuringiensis* (B.t.). Delta-endotoxins have been successfully expressed in crop plants such as cotton, potatoes, rice, sunflower, as well as corn, and have proven to provide excellent control over insect pests. (Perlak, F. J. et al. (1990) *Bio/Technology* 8, 939-943; Perlak, F. J. et al. (1993) *Plant Mol. Biol.* 22: 313-321; Fujimoto H. et al. (1993)

Bio/Technology 11: 1151-1155; Tu et al. (2000) *Nature Biotechnology* 18:1101-1104; PCT publication number WO 01/13731; and Bing J W et al. (2000) Efficacy of Cry1F Transgenic Maize, 14th Biennial International Plant Resistance to Insects Workshop, Fort Collins, Colo.)

[0008] Several Bt proteins have been used to create the insect-resistant transgenic plants that have been successfully registered and commercialized to date. These include Cry1Ab, Cry1Ac, Cry1F, Cry3Aa, and Cry3Bb in corn, Cry1Ac and Cry2Ab in cotton, and Cry3A in potato. There is also SMART STAX in corn, which comprises Cry1A.105 and Cry2Ab.

[0009] The commercial products expressing these proteins express a single protein except in cases where the combined insecticidal spectrum of 2 proteins is desired (e.g., Cry1Ab and Cry3Bb in corn combined to provide resistance to lepidopteran pests and rootworm, respectively) or where the independent action of the proteins makes them useful as a tool for delaying the development of resistance in susceptible insect populations (e.g., Cry1Ac and Cry2Ab in cotton combined to provide resistance management for tobacco budworm).

[0010] Some of the qualities of insect-resistant transgenic plants that have led to rapid and widespread adoption of this technology also give rise to the concern that pest populations will develop resistance to the insecticidal proteins produced by these plants. Several strategies have been suggested for preserving the utility of Bt-based insect resistance traits which include deploying proteins at a high dose in combination with a refuge, and alternation with, or co-deployment of, different toxins (McGaughey et al. (1998), "B.t. Resistance Management," *Nature Biotechnol.* 16:144-146).

[0011] The proteins selected for use in an Insect Resistance Management (IRM) stack should be active such that resistance developed to one protein does not confer resistance to the second protein (i.e., there is not cross resistance to the proteins). If, for example, a pest population selected for resistance to "Protein A" is sensitive to "Protein B", one would conclude that there is not cross resistance and that a combination of Protein A and Protein B would be effective in delaying resistance to Protein A alone.

[0012] In the absence of resistant insect populations, assessments can be made based on other characteristics presumed to be related to cross-resistance potential. The utility of receptor-mediated binding in identifying insecticidal proteins likely to not exhibit cross resistance has been suggested (van Mellaert et al. 1999). The key predictor of lack of cross resistance inherent in this approach is that the insecticidal proteins do not compete for receptors in a sensitive insect species.

[0013] In the event that two Bt toxins compete for the same receptor, then if that receptor mutates in that insect so that one of the toxins no longer binds to that receptor and thus is no longer insecticidal against the insect, it might be the case that the insect will also be resistant to the second toxin (which competitively bound to the same receptor). That is, the insect is said to be cross-resistant to both Bt toxins. However, if two toxins bind to two different receptors, this could be an indication that the insect would not be simultaneously resistant to those two toxins.

[0014] A relatively newer insecticidal protein system was discovered in *Bacillus thuringiensis* as disclosed in WO 97/40162. This system comprises two proteins—one of approximately 15 kDa and the other of about 45 kDa. See also U.S. Pat. Nos. 6,083,499 and 6,127,180. These proteins have

now been assigned to their own classes, and accordingly received the Cry designations of Cry34 and Cry35, respectively. See Crickmore et al. website (biols.susx.ac.uk/home/Neil_Crickmore/Bt/). Many other related proteins of this type of system have now been disclosed. See e.g. U.S. Pat. No. 6,372,480; WO 01/14417; and WO 00/66742. Plant-optimized genes that encode such proteins, wherein the genes are engineered to use codons for optimized expression in plants, have also been disclosed. See e.g. U.S. Pat. No. 6,218,188.

[0015] The exact mode of action of the Cry34/35 system has yet to be determined, but it appears to form pores in membranes of insect gut cells. See Moellenbeck et al., *Nature Biotechnology*, vol. 19, p. 668 (July 2001); Masson et al., *Biochemistry*, 43 (12349-12357) (2004). The exact mechanism of action remains unclear despite 3D atomic coordinates and crystal structures being known for a Cry34 and a Cry35 protein. See U.S. Pat. Nos. 7,524,810 and 7,309,785. For example, it is unclear if one or both of these proteins bind a typical type of receptor, such as an alkaline phosphatase or an aminopeptidase.

[0016] Furthermore, because there are different mechanisms by which an insect can develop resistance to a Cry protein (such as by altered glycosylation of the receptor [see Jurat-Fuentes et al. (2002) 68 *AEM* 5711-5717], by removal of the receptor protein [see Lee et al. (1995) 61 *AEM* 3836-3842], by mutating the receptor, or by other mechanisms [see Heckel et al., *J. Inv. Pathol.* 95 (2007) 192-197]), it was impossible to a priori predict whether there would be cross-resistance between Cry34/35 and other Cry proteins. Predicting competitive binding for the Cry34/35 system is also further complicated by the fact that two proteins are involved in the Cry34/35 binary system. Again, it is unclear if and how these proteins effectively bind the insect gut/gut cells, and if and how they interact with or bind with each other.

[0017] Other options for controlling coleopterans include the following proteins: Cry3Bb, Cry3C, Cry6B, ET29, ET33 with ET34, TIC407, TIC435, TIC417, TIC901, TIC1201, ET29 with TIC810, ET70, ET76 with ET80, TIC851, and others. RNAi approaches have also been proposed. See e.g. Baum et al., *Nature Biotechnology*, vol. 25, no. 11 (November 2007) pp. 1322-1326.

BRIEF SUMMARY

[0018] The subject invention relates in part to Cry34Ab/35Ab in combination with Cry3Ba. The subject invention relates in part to the surprising discovery that Cry34Ab/35Ab and Cry3Ba are useful for preventing development of resistance (to either insecticidal protein system alone) by a corn rootworm (*Diabrotica* spp.) population. As one skilled in the art will recognize with the benefit of this disclosure, plants producing these insecticidal Cry proteins will be useful to mitigate concern that a corn rootworm population could develop that would be resistant to either of these insecticidal protein systems alone.

[0019] The subject invention is supported in part by the discovery that components of these Cry protein systems do not compete with each other for binding corn rootworm gut receptors.

[0020] The subject invention also relates in part to triple stacks or "pyramids" of three (or more) toxin systems, with Cry34Ab/Cry35Ab and Cry3Ba being the base pair. Thus, plants (and acreage planted with such plants) that produce these two insecticidal protein systems are included within the scope of the subject invention.

BRIEF DESCRIPTION OF THE FIGURES

[0021] The detailed description of the drawings particularly refers to the accompanying figures in which:

[0022] FIG. 1A. Binding of ¹²⁵I-Cry35Ab1 as a function of input radio-labeled Cry toxins to BBMV prepared from western corn rootworm larvae. Specific binding=total binding-non-specific binding, error bar=SEM (standard error of mean).

[0023] FIG. 1B. Binding of ¹²⁵I-Cry3BAa1 as a function of input radio-labeled Cry toxins to BBMV prepared from western corn rootworm larvae. Specific binding=total binding-non-specific binding, error bar=SEM (standard error of mean).

[0024] FIG. 2. Binding of ¹²⁵I-Cry35Ab1 to BBMV prepared from western corn rootworm larvae at different concentrations of non-labeled competitor (log 0.1=1.0, log 10=1.0, log 100=2.0, log 1,000=3.0).

[0025] FIG. 3A. Percent binding of ¹²⁵I-Cry35Ab1 to BBMV prepared from western corn rootworm larvae in absence of Cry34Ab1.

[0026] FIG. 3B. Percent binding of ¹²⁵I-Cry35Ab1 to BBMV prepared from western corn rootworm larvae in presence of Cry34Ab1.

[0027] FIG. 4. Percent binding of ¹²⁵I-Cry3Ba1 to BBMV prepared from western corn rootworm larvae in presence of various concentrations of varying non-labeled competitors.

BRIEF DESCRIPTION OF THE SEQUENCES

[0028] SEQ ID NO:1: Full length, native Cry35Ab1 protein sequence.

[0029] SEQ ID NO:2: Chymotrypsin-truncated Cry35Ab1 core protein sequence.

[0030] SEQ ID NO:3: Full length, native Cry3Ba1 protein sequence.

[0031] SEQ ID NO:4: Cry3Ba1 trypsin core protein sequence.

[0032] SEQ ID NO:5: Full length, native Cry34Ab1 protein sequence.

DETAILED DESCRIPTION

[0033] Sequences for the Cry34Ab/35Ab protein are obtainable from *Bacillus thuringiensis* isolate PS149B1, for example. For other genes, protein sequences, and source isolates for use according to the subject invention, see the Crickmore et al. website (lifesci.sussex.ac.uk/home/Neil_Crickmore/Bt/intro.html), for example.

[0034] The subject invention includes the use of Cry34Ab/35Ab insecticidal proteins in combination with a Cry3Ba toxin to protect corn from damage and yield loss caused by corn rootworm feeding by corn rootworm populations that might develop resistance to either of these Cry protein systems alone (without the other).

[0035] The subject invention thus teaches Insect Resistance Management (IRM) stacks to prevent the development of resistance by corn rootworm to Cry3Ba and/or Cry34Ab/35Ab.

[0036] The present invention provides compositions for controlling rootworm pests comprising cells that produce a Cry3Ba toxin protein and a Cry34Ab/35Ab toxin system.

[0037] The invention further comprises a host transformed to produce both a Cry3Ba protein and a Cry34Ab/35Ab binary toxin, wherein said host is a microorganism or a plant cell.

[0038] It is additionally intended that the invention provides a method of controlling rootworm pests comprising contacting said pests or the environment of said pests with an effective amount of a composition that contains a Cry3Ba protein and further contains a Cry34Ab/35Ab binary toxin.

[0039] An embodiment of the invention comprises a maize plant comprising a plant-expressible gene encoding a Cry34Ab/35Ab binary toxin and a plant-expressible gene encoding a Cry3Ba protein, and seed of such a plant.

[0040] A further embodiment of the invention comprises a maize plant wherein a plant-expressible gene encoding a Cry34Ab/35Ab binary toxin and a plant-expressible gene encoding a Cry3Ba protein have been introgressed into said maize plant, and seed of such a plant.

[0041] As described in the Examples, competitive receptor binding studies using radiolabeled Cry35Ab core toxin protein show that the Cry3Ba core toxin protein does not compete for binding in CRW insect tissue samples to which Cry35Ab binds. See FIG. 2. These results indicate that the combination of Cry3Ba and Cry34Ab/35Ab proteins is an effective means to mitigate the development of resistance in CRW populations to either protein system alone.

[0042] Thus, based in part on the data described above and elsewhere herein, Cry34Ab/35Ab and Cry3Ba proteins can be used to produce IRM combinations for prevention or mitigation of resistance development by CRW. Other proteins can be added to this combination to expand insect-control spectrum, for example. The subject combination (of Cry34Ab/35Ab and Cry3Ba proteins) can also be used in some preferred “triple stacks” or “pyramids” in combination with yet another protein for controlling rootworms, such as Cry3Aa and/or Cry6Aa; such additional combinations would thus provide multiple modes of action against a rootworm. RNAi against rootworms is a still further option. See e.g. Baum et al., *Nature Biotechnology*, vol. 25, no. 11 (November 2007) pp. 1322-1326.

[0043] In light of the disclosure of U.S. Ser. No. 61/327,240 (filed Apr. 23, 2010) relating to combinations of Cry34Ab/35Ab and Cry3Aa proteins, U.S. Ser. No. 61/388,273 (filed Sep. 30, 2010) relating to combinations of Cry34Ab/35Ab and Cry6Aa proteins, and U.S. Ser. No. 61/477,447 (filed Sep. 20, 2011) relating to combinations of Cry3Aa and Cry6Aa proteins, some preferred “triple stacks” or “multiple modes of action stacks” of the subject invention include a Cry3Ba protein combined with Cry34Ab/35Ab proteins, together with a Cry6Aa protein and/or a Cry3Aa protein. Transgenic plants, including corn, comprising a cry3Ba gene, cry34Ab/35Ab genes, and a third or fourth toxin system (e.g., cry3Aa and/or cry6Aa gene(s)) are included within the scope of the subject invention. Thus, such embodiments target the insect with at least three modes of action.

[0044] Deployment options of the subject invention include the use of Cry3Ba and Cry34Ab/35Ab proteins in corn-growing regions where *Diabrotica* spp. are problematic. Another deployment option would be to use one or both of the Cry3Ba and Cry34Ab/35Ab proteins in combination with other traits.

[0045] A person skilled in this art will appreciate that Bt toxins, even within a certain class such as Cry3Ba and Cry34Ab/35Ab can vary to some extent.

[0046] Genes and toxins. The term “isolated” refers to a polynucleotide in a non-naturally occurring construct, or to a protein in a purified or otherwise non-naturally occurring state. The genes and toxins useful according to the subject invention include not only the full length sequences disclosed

but also fragments of these sequences, variants, mutants, and fusion proteins which retain the characteristic pesticidal activity of the toxins specifically exemplified herein. As used herein, the terms “variants” or “variations” of genes refer to nucleotide sequences which encode the same toxins or which encode equivalent toxins having pesticidal activity. As used herein, the term “equivalent toxins” refers to toxins having the same or essentially the same biological activity against the target pests as the claimed toxins. This applies to Cry3’s and Cry34/35’s, as well as Cry6’s (if used in triple/multiple stacks) according to the subject invention. Domains/subdomains of these proteins can be swapped to make chimeric proteins. See e.g. U.S. Pat. Nos. 7,309,785 and 7,524,810 regarding Cry34/35 proteins. The ’785 patent also teaches truncated Cry35 proteins. Truncated toxins are also exemplified herein.

[0047] As used herein, the boundaries represent approximately 95% (Cry3Ba’s and Cry34Ab’s and Cry35Ab’s), 78% (Cry3B’s and Cry 34A’s and Cry35A’s), and 45% (Cry6’s and Cry 34’s and Cry 35’s) sequence identity, per “Revision of the Nomenclature for the *Bacillus thuringiensis* Pesticidal Crystal Proteins,” N. Crickmore, D. R. Zeigler, J. Feitelson, E. Schnepf, J. Van Rie, D. Lereclus, J. Baum, and D. H. Dean. *Microbiology and Molecular Biology Reviews* (1998) Vol 62: 807-813. The same applies to Cry3A’s and/or Cry6’s if used in triple/multiple stacks, for example, according to the subject invention.

[0048] It should be apparent to a person skilled in this art that genes encoding active toxins can be identified and obtained through several means. The specific genes or gene portions exemplified herein may be obtained from the isolates deposited at a culture depository. These genes, or portions or variants thereof, may also be constructed synthetically, for example, by use of a gene synthesizer. Variations of genes may be readily constructed using standard techniques for making point mutations. Also, fragments of these genes can be made using commercially available exonucleases or endonucleases according to standard procedures. For example, enzymes such as Ba131 or site-directed mutagenesis can be used to systematically cut off nucleotides from the ends of these genes. Genes that encode active fragments may also be obtained using a variety of restriction enzymes. Proteases may be used to directly obtain active fragments of these protein toxins.

[0049] Fragments and equivalents which retain the pesticidal activity of the exemplified toxins would be within the scope of the subject invention. Also, because of the redundancy of the genetic code, a variety of different DNA sequences can encode the amino acid sequences disclosed herein. It is well within the skill of a person trained in the art to create these alternative DNA sequences encoding the same, or essentially the same, toxins. These variant DNA sequences are within the scope of the subject invention. As used herein, reference to “essentially the same” sequence refers to sequences which have amino acid substitutions, deletions, additions, or insertions which do not materially affect pesticidal activity. Fragments of genes encoding proteins that retain pesticidal activity are also included in this definition.

[0050] A further method for identifying the genes encoding the toxins and gene portions useful according to the subject invention is through the use of oligonucleotide probes. These probes are detectable nucleotide sequences. These sequences may be detectable by virtue of an appropriate label or may be made inherently fluorescent as described in International

Application No. WO93/16094. As is well known in the art, if the probe molecule and nucleic acid sample hybridize by forming a strong bond between the two molecules, it can be reasonably assumed that the probe and sample have substantial homology. Preferably, hybridization is conducted under stringent conditions by techniques well-known in the art, as described, for example, in Keller, G. H., M. M. Manak (1987) DNA Probes, Stockton Press, New York, N.Y., pp. 169-170. Some examples of salt concentrations and temperature combinations are as follows (in order of increasing stringency): 2× SSPE or SSC at room temperature; 1× SSPE or SSC at 42° C.; 0.1× SSPE or SSC at 42° C.; 0.1× SSPE or SSC at 65° C. Detection of the probe provides a means for determining in a known manner whether hybridization has occurred. Such a probe analysis provides a rapid method for identifying toxin-encoding genes of the subject invention. The nucleotide segments which are used as probes according to the invention can be synthesized using a DNA synthesizer and standard procedures. These nucleotide sequences can also be used as PCR primers to amplify genes of the subject invention.

[0051] Variant toxins. Certain toxins of the subject invention have been specifically exemplified herein. Since these toxins are merely exemplary of the toxins of the subject invention, it should be readily apparent that the subject invention comprises variant or equivalent toxins (and nucleotide sequences coding for equivalent toxins) having the same or similar pesticidal activity of the exemplified toxin. Equivalent toxins will have amino acid homology with an exemplified toxin. This amino acid identity will typically be greater than 75%, or preferably greater than 85%, preferably greater than 90%, preferably greater than 95%, preferably greater than 96%, preferably greater than 97%, preferably greater than 98%, or preferably greater than 99% in some embodiments. The amino acid identity will typically be highest in critical regions of the toxin which account for biological activity or are involved in the determination of three-dimensional configuration which ultimately is responsible for the biological activity. In this regard, certain amino acid substitutions are acceptable and can be expected if these substitutions are in regions which are not critical to activity or are conservative amino acid substitutions which do not affect the three-dimensional configuration of the molecule. For example, amino acids may be placed in the following classes: non-polar, uncharged polar, basic, and acidic. Conservative substitutions whereby an amino acid of one class is replaced with another amino acid of the same type fall within the scope of the subject invention so long as the substitution does not materially alter the biological activity of the compound. Table 1 provides a listing of examples of amino acids belonging to each class.

TABLE 1

Classes of amino acids with examples of amino acids belonging to each class	
Class of Amino Acid	Examples of Amino Acids
Nonpolar	Ala, Val, Leu, Ile, Pro, Met, Phe, Trp
Uncharged Polar	Gly, Ser, Thr, Cys, Tyr, Asn, Gln

TABLE 1-continued

Classes of amino acids with examples of amino acids belonging to each class	
Class of Amino Acid	Examples of Amino Acids
Acidic	Asp, Glu
Basic	Lys, Arg, His

[0052] In some instances, non-conservative substitutions can also be made. The critical factor is that these substitutions must not significantly detract from the biological activity of the toxin.

[0053] Recombinant hosts. The genes encoding the toxins of the subject invention can be introduced into a wide variety of microbial or plant hosts. Expression of the toxin gene results, directly or indirectly, in the intracellular production and maintenance of the pesticide. Conjugal transfer and recombinant transfer can be used to create a Bt strain that expresses both toxins of the subject invention. Other host organisms may also be transformed with one or both of the toxin genes then used to accomplish the synergistic effect. With suitable microbial hosts, e.g., *Pseudomonas*, the microbes can be applied to the situs of the pest, where they will proliferate and be ingested. The result is control of the pest. Alternatively, the microbe hosting the toxin gene can be treated under conditions that prolong the activity of the toxin and stabilize the cell. The treated cell, which retains the toxic activity, then can be applied to the environment of the target pest. Non-regenerable/non-totipotent plant cells from a plant of the subject invention (comprising at least one of the subject IRM genes) are included within the subject invention.

[0054] Plant transformation. A preferred embodiment of the subject invention is the transformation of plants with genes encoding the subject insecticidal protein or its variants. The transformed plants are resistant to attack by an insect target pest by virtue of the presence of controlling amounts of the subject insecticidal protein or its variants in the cells of the transformed plant. By incorporating genetic material that encodes the insecticidal properties of the B.t. insecticidal toxins into the genome of a plant eaten by a particular insect pest, the adult or larvae would die after consuming the food plant. Numerous members of the monocotyledonous and dicotyledonous classifications have been transformed. Transgenic agronomic crops as well as fruits and vegetables are of commercial interest. Such crops include, but are not limited to, maize, rice, soybeans, canola, sunflower, alfalfa, sorghum, wheat, cotton, peanuts, tomatoes, potatoes, and the like. Several techniques exist for introducing foreign genetic material into plant cells, and for obtaining plants that stably maintain and express the introduced gene. Such techniques include acceleration of genetic material coated onto microparticles directly into cells (U.S. Pat. No. 4,945,050 and U.S. Pat. No. 5,141,131). Plants may be transformed using *Agrobacterium* technology, see U.S. Pat. No. 5,177,010, U.S. Pat. No. 5,104,310, European Patent Application No. 0131624B1, European Patent Application No. 120516, European Patent Application No. 159418B1, European Patent Application No. 176112, U.S. Pat. No. 5,149,645, U.S. Pat. No. 5,469,976, U.S. Pat. No. 5,464,763, U.S. Pat. No. 4,940,838, U.S. Pat. No. 4,693,976, European Patent Application No. 116718, European

Patent Application No. 290799, European Patent Application No. 320500, European Patent Application No. 604662, European Patent Application No. 627752, European Patent Application No. 0267159, European Patent Application No. 0292435, U.S. Pat. No. 5,231,019, U.S. Pat. No. 5,463,174, U.S. Pat. No. 4,762,785, U.S. Pat. No. 5,004,863, and U.S. Pat. No. 5,159,135. Other transformation technology includes WHISKERS™ technology, see U.S. Pat. No. 5,302,523 and U.S. Pat. No. 5,464,765. Electroporation technology has also been used to transform plants, see WO 87/06614, U.S. Pat. No. 5,472,869, U.S. Pat. No. 5,384,253, WO 9209696, and WO 9321335. All of these transformation patents and publications are incorporated by reference. In addition to numerous technologies for transforming plants, the type of tissue which is contacted with the foreign genes may vary as well. Such tissue would include but would not be limited to embryogenic tissue, callus tissue types I and II, hypocotyl, meristem, and the like. Almost all plant tissues may be transformed during dedifferentiation using appropriate techniques within the skill of an artisan.

[0055] Genes encoding any of the subject toxins can be inserted into plant cells using a variety of techniques which are well known in the art as disclosed above. For example, a large number of cloning vectors comprising a marker that permits selection of the transformed microbial cells and a replication system functional in *Escherichia coli* are available for preparation and modification of foreign genes for insertion into higher plants. Such manipulations may include, for example, the insertion of mutations, truncations, additions, or substitutions as desired for the intended use. The vectors comprise, for example, pBR322, pUC series, M13mp series, pACYC184, etc. Accordingly, the sequence encoding the Cry protein or variants can be inserted into the vector at a suitable restriction site. The resulting plasmid is used for transformation of cells of *E. coli*, the cells of which are cultivated in a suitable nutrient medium, then harvested and lysed so that workable quantities of the plasmid are recovered. Sequence analysis, restriction fragment analysis, electrophoresis, and other biochemical-molecular biological methods are generally carried out as methods of analysis. After each manipulation, the DNA sequence used can be cleaved and joined to the next DNA sequence. Each manipulated DNA sequence can be cloned in the same or other plasmids.

[0056] The use of T-DNA-containing vectors for the transformation of plant cells has been intensively researched and sufficiently described in EP 120516; Lee and Gelvin (2008), Fraley et al. (1986), and An et al. (1985), and is well established in the field.

[0057] Once the inserted DNA has been integrated into the plant genome, it is relatively stable throughout subsequent generations. The vector used to transform the plant cell normally contains a selectable marker gene encoding a protein that confers on the transformed plant cells resistance to a herbicide or an antibiotic, such as bialaphos, kanamycin, G418, bleomycin, or hygromycin, inter alia. The individually employed selectable marker gene should accordingly permit the selection of transformed cells while the growth of cells that do not contain the inserted DNA is suppressed by the selective compound.

[0058] A large number of techniques are available for inserting DNA into a host plant cell. Those techniques include transformation with T-DNA delivered by *Agrobacterium tumefaciens* or *Agrobacterium rhizogenes* as the transformation agent. Additionally, fusion of plant protoplasts with lipo-

somes containing the DNA to be delivered, direct injection of the DNA, biolistics transformation (microparticle bombardment), or electroporation, as well as other possible methods, may be employed.

[0059] In a preferred embodiment of the subject invention, plants will be transformed with genes wherein the codon usage of the protein coding region has been optimized for plants. See, for example, U.S. Pat. No. 5,380,831, which is hereby incorporated by reference. Also, advantageously, plants encoding a truncated toxin will be used. The truncated toxin typically will encode about 55% to about 80% of the full length toxin. Methods for creating synthetic B.t. genes for use in plants are known in the art (Stewart, 2007).

[0060] Regardless of transformation technique, the gene is preferably incorporated into a gene transfer vector adapted to express the B.t. insecticidal toxin genes and variants in the plant cell by including in the vector a plant promoter. In addition to plant promoters, promoters from a variety of sources can be used efficiently in plant cells to express foreign genes. For example, one may use promoters of bacterial origin, such as the octopine synthase promoter, the nopaline synthase promoter, and the mannopine synthase promoter. Non-*Bacillus-thuringiensis* promoters can be used in some preferred embodiments. Promoters of plant virus origin may be used, for example, the 35S and 19S promoters of Cauliflower Mosaic Virus, a promoter from Cassava Vein Mosaic Virus, and the like. Plant promoters include, but are not limited to, ribulose-1,6-bisphosphate (RUBP) carboxylase small subunit (ssu), beta-conglycinin promoter, phaseolin promoter, ADH (alcohol dehydrogenase) promoter, heat-shock promoters, ADF (actin depolymerization factor) promoter, ubiquitin promoter, actin promoter, and tissue specific promoters. Promoters may also contain certain enhancer sequence elements that may improve the transcription efficiency. Typical enhancers include but are not limited to ADH1-intron 1 and ADH1-intron 6. Constitutive promoters may be used. Constitutive promoters direct continuous gene expression in nearly all cells types and at nearly all times (e.g., actin, ubiquitin, CaMV 35S). Tissue specific promoters are responsible for gene expression in specific cell or tissue types, such as the leaves or seeds (e.g. zein, oleosin, napin, ACP (Acyl Carrier Protein) promoters), and these promoters may also be used. Promoters may also be used that are active during a certain stage of the plants' development as well as active in specific plant tissues and organs. Examples of such promoters include but are not limited to promoters that are root specific, pollen-specific, embryo specific, corn silk specific, cotton fiber specific, seed endosperm specific, phloem specific, and the like.

[0061] Under certain circumstances it may be desirable to use an inducible promoter. An inducible promoter is responsible for expression of genes in response to a specific signal, such as: physical stimulus (e.g. heat shock genes); light (e.g. RUBP carboxylase); hormone (e.g. glucocorticoid); antibiotic (e.g. tetracycline); metabolites; and stress (e.g. drought). Other desirable transcription and translation elements that function in plants may be used, such as 5' untranslated leader sequences, RNA transcription termination sequences and poly-adenylate addition signal sequences. Numerous plant-specific gene transfer vectors are known to the art.

[0062] Transgenic crops containing insect resistance (IR) traits are prevalent in corn and cotton plants throughout North America, and usage of these traits is expanding globally. Commercial transgenic crops combining IR and herbicide

tolerance (HT) traits have been developed by multiple seed companies. These include combinations of IR traits conferred by B.t. insecticidal proteins and HT traits such as tolerance to Acetolactate Synthase (ALS) inhibitors such as sulfonylureas, imidazolinones, triazolopyrimidine, sulfonanilides, and the like, Glutamine Synthetase (GS) inhibitors such as bialaphos, glufosinate, and the like, 4-HydroxyPhenylPyruvate Dioxygenase (HPPD) inhibitors such as mesotrione, isoxaflutole, and the like, 5-EnolPyruvylShikimate-3-Phosphate Synthase (EPSPS) inhibitors such as glyphosate and the like, and Acetyl-Coenzyme A Carboxylase (ACCase) inhibitors such as haloxyfop, quizalofop, diclofop, and the like. Other examples are known in which transgenically provided proteins provide plant tolerance to herbicide chemical classes such as phenoxy acids herbicides and pyridyloxyacetates auxin herbicides (see WO 2007/053482 A2), or phenoxy acids herbicides and aryloxyphenoxypropionates herbicides (see WO 2005/107437 A2, A3). The ability to control multiple pest problems through IR traits is a valuable commercial product concept, and the convenience of this product concept is enhanced if insect control traits and weed control traits are combined in the same plant. Further, improved value may be obtained via single plant combinations of IR traits conferred by a B.t. insecticidal protein such as that of the subject invention, with one or more additional HT traits such as those mentioned above, plus one or more additional input traits (e.g. other insect resistance conferred by B.t.-derived or other insecticidal proteins, insect resistance conferred by mechanisms such as RNAi and the like, nematode resistance, disease resistance, stress tolerance, improved nitrogen utilization, and the like), or output traits (e.g. high oils content, healthy oil composition, nutritional improvement, and the like). Such combinations may be obtained either through conventional breeding (breeding stack) or jointly as a novel transformation event involving the simultaneous introduction of multiple genes (molecular stack). Benefits include the ability to manage insect pests and improved weed control in a crop plant that provides secondary benefits to the producer and/or the consumer. Thus, the subject invention can be used in combination with other traits to provide a complete agronomic package of improved crop quality with the ability to flexibly and cost effectively control any number of agronomic issues.

[0063] The transformed cells grow inside the plants in the usual manner. They can form germ cells and transmit the transformed trait(s) to progeny plants.

[0064] Such plants can be grown in the normal manner and crossed with plants that have the same transformed hereditary factors or other hereditary factors. The resulting hybrid individuals have the corresponding phenotypic properties.

[0065] In a preferred embodiment of the subject invention, plants will be transformed with genes wherein the codon usage has been optimized for plants. See, for example, U.S. Pat. No. 5,380,831. In addition, methods for creating synthetic Bt genes for use in plants are known in the art (Stewart and Burgin, 2007). One non-limiting example of a preferred transformed plant is a fertile maize plant comprising a plant expressible gene encoding a Cry3Ba protein, and further comprising a second set of plant expressible genes encoding Cry34Ab/35Ab proteins.

[0066] Transfer (or introgression) of the Cry3Ba- and Cry34Ab/35Ab-determined trait(s) into inbred maize lines can be achieved by recurrent selection breeding, for example by backcrossing. In this case, a desired recurrent parent is first

crossed to a donor inbred (the non-recurrent parent) that carries the appropriate gene(s) for the Cry-determined traits. The progeny of this cross is then mated back to the recurrent parent followed by selection in the resultant progeny for the desired trait(s) to be transferred from the non-recurrent parent. After three, preferably four, more preferably five or more generations of backcrosses with the recurrent parent with selection for the desired trait(s), the progeny will be heterozygous for loci controlling the trait(s) being transferred, but will be like the recurrent parent for most or almost all other genes (see, for example, Poehlman & Sleper (1995) *Breeding Field Crops*, 4th Ed., 172-175; Fehr (1987) *Principles of Cultivar Development*, Vol. 1: Theory and Technique, 360-376).

[0067] Insect Resistance Management (IRM) Strategies. Roush et al., for example, outlines two-toxin strategies, also called "pyramiding" or "stacking," for management of insecticidal transgenic crops. (The Royal Society. *Phil. Trans. R. Soc. Lond. B.* (1998) 353, 1777-1786).

[0068] On their website, the United States Environmental Protection Agency (epa.gov/opppbpd1/biopesticides/pips/bt_corn_refuge_2006.htm) publishes the following requirements for providing non-transgenic (i.e., non-B.t.) refuges (a block of non-Bt crops/corn) for use with transgenic crops producing a single Bt protein active against target pests.

[0069] "The specific structured requirements for corn borer-protected Bt (Cry1Ab or Cry1F) corn products are as follows:

[0070] Structured refuges: 20% non-Lepidopteran Bt corn refuge in Corn Belt;

[0071] 50% non-Lepidopteran Bt refuge in Cotton Belt

[0072] Blocks

[0073] Internal (i.e., within the Bt field)

[0074] External (i.e., separate fields within 1/2 mile (1/4 mile if possible) of the Bt field to maximize random mating)

[0075] In-field Strips

[0076] Strips must be at least 4 rows wide (preferably 6 rows) to reduce the effects of larval movement"

[0077] In addition, the National Corn Growers Association, on their website:

[0078] (ncga.com/insect-resistance-management-fact-sheet-bt-corn) also provides similar guidance regarding the refuge requirements. For example:

[0079] "Requirements of the Corn Borer IRM:

[0080] Plant at least 20% of your corn acres to refuge hybrids

[0081] In cotton producing regions, refuge must be 50%

[0082] Must be planted within 1/2 mile of the refuge hybrids

[0083] Refuge can be planted as strips within the Bt field; the refuge strips must be at least 4 rows wide

[0084] Refuge may be treated with conventional pesticides only if economic thresholds are reached for target insect

[0085] Bt-based sprayable insecticides cannot be used on the refuge corn

[0086] Appropriate refuge must be planted on every farm with Bt corn"

[0087] As stated by Roush et al. (on pages 1780 and 1784 right column, for example), stacking or pyramiding of two different proteins each effective against the target pests and with little or no cross-resistance can allow for use of a smaller refuge. Roush suggests that for a successful stack, a refuge

size of less than 10% refuge, can provide comparable resistance management to about 50% refuge for a single (non-pyramided) trait. For currently available pyramided Bt corn products, the U.S. Environmental Protection Agency requires significantly less (generally 5%) structured refuge of non-Bt corn be planted than for single trait products (generally 20%).

[0088] There are various ways of providing the IRM effects of a refuge, including various geometric planting patterns in the fields (as mentioned above) and in-bag seed mixtures, as discussed further by Roush et al. (supra), and U.S. Pat. No. 6,551,962.

[0089] The above percentages, or similar refuge ratios, can be used for the subject double or triple stacks or pyramids. Because the subject invention provides multiple, non-competitive modes of action against a rootworm target insect, the subject invention could provide “zero refuge”, that is, a field that lacks refuge plants (because they are not required). A permit is typically required for typical B.t. transgenic fields of above about 10 acres. Thus, the subject invention includes a field of 10 acres or more with “zero refuge” or no Bt plants; fields of this size would previously have been required to have a significant non-Bt refuge.

[0090] All patents, patent applications, provisional applications, and publications referred to or cited herein are incorporated by reference in their entirety to the extent they are not inconsistent with the explicit teachings of this specification.

[0091] Following are examples that illustrate procedures for practicing the invention. These examples should not be construed as limiting. All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted. All temperatures are in degrees Celsius.

[0092] Unless specifically indicated or implied, the terms “a”, “an”, and “the” signify “at least one” as used herein.

EXAMPLES

Example 1

Construction of Expression Plasmids Encoding Cry34Ab1, Cry35Ab1, and Cry3Ba1 Full-Length Toxins

[0093] Standard cloning methods were used in the construction of *Pseudomonas fluorescens* (Pf) expression plasmids engineered to produce full-length Cry34Ab1, Cry35Ab1, and Cry3Ba1 Cry proteins respectively. Restriction endonucleases from New England BioLabs (NEB; Ipswich, Mass.) were used for DNA digestion and T4 DNA Ligase from Invitrogen was used for DNA ligation. Plasmid preparations were performed using the Plasmid Midi Kit (Qiagen), following the instructions of the supplier. DNA fragments were purified using the Millipore Ultrafree®-DA cartridge (Billerica, Mass.) after agarose Tris-acetate gel electrophoresis. The basic cloning strategy entailed subcloning the coding sequences (CDS) of a full-length Cry34Ab1 and Cry35Ab1 proteins into pMYC 1803 at SpeI and XhoI (or XbaI) restriction sites, and the CDS of a full-length Cry3Ba1 protein into pMYC1050 at KpnI and XbaI restriction sites, respectively, whereby they were placed under the expression control of the Ptac promoter and the rrnBT1T2 terminator from plasmid pKK223-3 (PL Pharmacia, Milwaukee, Wis.), respectively. pMYC1803 is a medium copy plasmid with the RSF1010 origin of replication, a tetracycline resistance gene, and a ribosome binding site preceding the restriction enzyme recognition sites into which DNA fragments containing pro-

tein coding regions may be introduced (U.S. Patent Application No. 2008/0193974). The expression plasmid was transformed by electroporation into a *P. fluorescens* strain MB214, recovered in SOC-Soy hydrolysate medium, and plated on Lysogeny broth (LB) medium containing 20 µg/ml tetracycline. Details of the microbiological manipulations are available U.S. Patent Application No. 2006/0008877, U.S. Patent Application No. 2008/0193974, and U.S. Patent Application No. 2008/0058262, incorporated herein by reference. Colonies were screened by restriction digestion of miniprep plasmid DNA. Plasmid DNA of selected clones containing inserts was sequenced by contract with a commercial sequencing vendor such as MWG Biotech (Huntsville, Ala.). Sequence data were assembled and analyzed using the Sequencher™ software (Gene Codes Corp., Ann Arbor, Mich.).

Example 2

Growth and Expression

[0094] Growth and expression analysis in shake flasks production of Cry34Ab1, Cry35Ab1, and Cry3Ba1 toxins for characterization including Bt receptor binding and insect bioassay was accomplished by shake-flask-grown *P. fluorescens* strains harboring expression constructs (e.g. clone pMYC2593 for Cry34Ab1, pMYC3122 for Cry35Ab1, and pMYC1177 for Cry3Ba1). Seed cultures grown in LB medium supplemented with 20 µg/ml tetracycline were used to inoculate 200 mL of the same medium with 20 µg/ml tetracycline. Expression of Cry34Ab1, Cry35Ab1, and Cry3Ba1 toxins via the Ptac promoter was induced by addition of isopropyl-β-D-1-thiogalactopyranoside (IPTG) after an initial incubation of 24 hours at 30° C. with shaking. Cultures were sampled at the time of induction and at various times post-induction. Cell density was measured by optical density at 600 nm (OD₆₀₀).

Example 3

Cell Fractionation and SDS-PAGE Analysis of Shake Flask Samples

[0095] At each sampling time, the cell density of samples was adjusted to OD₆₀₀=20 and 1 mL aliquots are centrifuged at 14,000×g for five minutes. The cell pellets were frozen at -80° C. Soluble and insoluble fractions from frozen shake flask cell pellet samples were generated using EasyLyse™ Bacterial Protein Extraction Solution (EPICENTRE® Biotechnologies, Madison, Wis.). Each cell pellet was resuspended in 1 mL EasyLyse™ solution and further diluted 1:4 in lysis buffer and incubated with shaking at room temperature for 30 minutes. The lysate was centrifuged at 14,000 rpm for 20 minutes at 4° C. and the supernatant was recovered as the soluble fraction. The pellet (insoluble fraction) was then resuspended in an equal volume of phosphate buffered saline (PBS; 11.9 mM Na₂HPO₄, 137 mM NaCl, 2.7 mM KCl, pH7.4). Samples were mixed 1:1 with 2× Laemmli sample buffer containing β-mercaptoethanol and boiled for 5 minutes prior to loading onto NuPAGE Novex 4-20% Bis-Tris gels (Invitrogen, Carlsbad, Calif.). Electrophoresis was performed in the recommended XT MOPS buffer. Gels were stained with the SimplyBlue™ Safe Stain according to the manufacturer's (Invitrogen) protocol and imaged using the Typhoon imaging system (GE Healthcare Life Sciences, Pittsburgh, Pa.).

Example 4

Inclusion Body Preparation

[0096] Cry protein inclusion body (IB) preparations were performed on cells from *P. fluorescens* fermentations that produced insoluble B.t. insecticidal protein, as demonstrated by SDS-PAGE and MALDI-MS (Matrix Assisted Laser Desorption/Ionization Mass Spectrometry). *P. fluorescens* fermentation pellets are thawed in a 37° C. water bath. The cells were resuspended to 25% w/v in lysis buffer [50 mM Tris, pH 7.5, 200 mM NaCl, 20 mM EDTA disodium salt (Ethylenediaminetetraacetic acid), 1% Triton X-100, and 5 mM Dithiothreitol (DTT)] and 5 mL/L of bacterial protease inhibitor cocktail (P8465 Sigma-Aldrich, St. Louis, Mo.) was added just prior to use. The cells were suspended using a homogenizer at lowest setting (Tissue Tearor, BioSpec Products, Inc., Bartlesville, Okla.). Lysozyme (25 mg of Sigma L7651, from chicken egg white) was added to the cell suspension by mixing with a metal spatula, and the suspension was incubated at room temperature for one hour. The suspension was cooled on ice for 15 minutes, then sonicated using a Branson Sonifier 250 (two 1-minute sessions, at 50% duty cycle, 30% output). Cell lysis was checked by microscopy. An additional 25 mg of lysozyme was added if necessary, and the incubation and sonication were repeated. When cell lysis was confirmed via microscopy, the lysate was centrifuged at 11,500×g for 25 minutes (4° C.) to form the IB pellet, and the supernatant was discarded. The IB pellet was resuspended with 100 mL lysis buffer, homogenized with the hand-held mixer and centrifuged as above. The IB pellet was repeatedly washed by resuspension (in 50 mL lysis buffer), homogenization, sonication, and centrifugation until the supernatant became colorless and the IB pellet became firm and off-white in color. For the final wash, the IB pellet was resuspended in sterile-filtered (0.22 µm) distilled water containing 2 mM EDTA, and centrifuged. The final pellet was resuspended in sterile-filtered distilled water containing 2 mM EDTA, and stored in 1 mL aliquots at -80° C.

Example 5

SDS-PAGE Analysis and Quantification

[0097] SDS-PAGE analysis and quantification of protein in IB preparations were done by thawing a 1 mL aliquot of IB pellet and diluting 1:20 with sterile-filtered distilled water. The diluted sample was then boiled with 4× reducing sample buffer [250 mM Tris, pH 6.8, 40% glycerol (v/v), 0.4% Bromophenol Blue (w/v), 8% SDS (w/v) and 8% β-Mercaptoethanol (v/v)] and loaded onto a Novex® 4-20% Tris-Glycine, 12+2 well gel (Invitrogen) run with 1× Tris/Glycine/SDS buffer (Invitrogen). The gel was run for approximately 60 min at 200 volts then stained and destained by following the SimplyBlue™ Safe Stain (Invitrogen) procedures. Quantification of target bands was done by comparing densitometric values for the bands against Bovine Serum Albumin (BSA) samples run on the same gel to generate a standard curve using the Bio-Rad Quantity One® software.

Example 6

Solubilization of Inclusion Bodies

[0098] Ten mL of inclusion body suspensions from *P. fluorescens* clones MR1253, MR1636, and MR816 (containing

50-70 mg/mL of Cry34Ab1, Cry35Ab1, and Cry3Ba1 proteins respectively) were centrifuged at the highest setting of an Eppendorf model 5415C microfuge (approximately 14,000×g) to pellet the inclusions. The storage buffer supernatant was removed and replaced with 25 mL of 100 mM sodium acetate buffer, pH 3.0, for both Cry34Ab1 and Cry35Ab1, and 100 mM sodium carbonate buffer, pH 11, for Cry3Ba1, in a 50 mL conical tube, respectively. Inclusions were resuspended using a pipette and vortexed to mix thoroughly. The tubes were placed on a gently rocking platform at 4° C. overnight to extract full-length Cry34Ab1, Cry35Ab1, and Cry3Ba1 proteins. The extracts were centrifuged at 30,000×g for 30 min at 4° C., and the resulting supernatants (containing solubilized full-length Cry proteins) were saved.

Example 7

Truncation of Full-Length Protoxins

[0099] Full-length Cry35Ab1 and Cry3Ba1 were truncated or digested with chymotrypsin or trypsin to produce chymotrypsin or trypsin core fragments that are an active form of the proteins. Specially, the solubilized full-length Cry35Ab1 was incubated with chymotrypsin (bovine pancreas) (Sigma, St. MO) (at 50:1 =Cry protein: enzyme, w/w) in the 100 mM sodium acetate buffer, pH 3.0 (Example 6), at 4° C. with gentle shaking for 2-3 days, while full-length Cry3Ba1 was incubated with trypsin (bovine pancreas) (Sigma, St. MO) (at 20:1=Cry protein: enzyme, w/w) in the 100 mM sodium carbonate buffer, pH 11 (Example 6), at room temperature for 1-3 hours. Complete proteolytic preprocessing was confirmed by SDS-PAGE analysis. The molecular mass of the full-length Cry35Ab1 and Cry3Ba1 was approximately equal to 44 and approximately equal to 73 kDa, and their chymotrypsin or trypsin core was approximately equal to 40 and approximately equal to 55 kDa, respectively. The amino acid sequences of full-length and chymotrypsin core of Cry35Ab1 are provided as SEQ ID 1 and SEQ ID 2, and the amino acid sequences of full-length and trypsin core of Cry3Ba1 are provided as SEQ ID 3 and SEQ ID 4. Either chymotrypsin or trypsin core is not available for Cry34Ab1, and thus the full-length Cry34Ab1 was used for binding assays. The amino acid sequence of the full-length Cry34Ab1 is provided as SEQ ID 5.

Example 8

Purification of Truncated Toxins

[0100] The chymotrypsinized Cry35Ab1 and trypsinized Cry3Ba1 core fragments were purified. Specifically, the digestion reactions were centrifuged at 30,000×g for 30 min at 4° C. to remove lipids, and the resulting supernatant were concentrated 5-fold using an Amicon Ultra-15 regenerated cellulose centrifugal filter device (10,000 Molecular Weight Cutoff; Millipore). The sample buffers were then changed to 20 mM sodium acetate buffer, pH 3.5, for both Cry34Ab1 and Cry35Ab1, and to 10 mM CAPS [3-(cyclohexamino)1-propanesulfonic acid], pH 10.5, for Cry3Ba1, using disposable PD-10 columns (GE Healthcare, Piscataway, N.J.) or dialysis. The final volumes were adjusted to 15 mL using the corresponding buffer for purification using ATKA Explorer liquid chromatography system (Amersham Biosciences). For Cry35Ab1, buffer A was 20 mM sodium acetate buffer, pH 3.5, and buffer B was buffer A+1 M NaCl, pH 3.5. A HiTrap SP (5 mL) column (GE) was used. After the column was fully

equilibrated using the buffer A, the Cry35Ab1 solution was injected into the column at a flow rate of 5 ml/min. Elution was performed using gradient 0-100% of buffer B at 5 ml/min with 1 ml/fraction. For Cry3Ba1, buffer A was 10 mM CAPS buffer, pH 10.5, and buffer B was 10 mM CAPS buffer, pH 10.5+1 M NaCl. A Capto Q, 5 ml (5 ml) column (GE) was used and all other procedures were similar to that for Cry35Ab1. After SDS-PAGE analysis of the selected fractions to further select fractions containing the best quality target protein, pooled those fractions. The buffer was changed for the purified Cry35Ab1 chymotrypsin core with 20 mM Bis-Tris, pH 6.0, as described above. For the purified Cry3Ba1 trypsin core, the salt was removed using disposable PD-10 columns (GE Healthcare, Piscataway, N.J.) or dialysis. The samples were saved at 4° C. for later binding assays after being quantified using SDS-PAGE and the Typhoon imaging system (GE) analysis with BSA as a standard.

Example 9

BBMV Preparation

[0101] Brush border membrane vesicle (BBMV) preparations of insects have been widely used for Cry toxin receptor binding assays. The BBMV preparations used in this invention were prepared from isolated midguts of third instars of the western corn rootworm (*Diabrotica virgifera virgifera* LeConte) using the method described by Wolferberger et al. (1987). Leucine aminopeptidase was used as a marker of membrane proteins in the preparation and Leucine aminopeptidase activities of crude homogenate and BBMV preparations were determined as previously described (Li et al. 2004a). Protein concentration of the BBMV preparations were measured using the Bradford method (1976).

Example 10

¹²⁵I Labeling

[0102] Purified full-length Cry34Ab1, chymotrypsinized Cry35Ab1, and trypsinized Cry3Ba1 were labeled using ¹²⁵I for saturation and homologous competition binding assays. To ensure the radio-labeling does not abolish the biological activity of the Cry toxins, cold iodination was conducted using NaI by following the instructions of Pierce® Iodination Beads (Pierce Biotechnology, Thermo Scientific, Rockford Ill.). Bioassay results indicated that iodinated Cry35Ab1 chymotrypsin core remained active against the larvae of the western corn rootworm, but iodination inactivated Cry34Ab1. The specific binding of radiolabeled ¹²⁵I-Cry34Ab1 to the insect BBMV was not able to be detected, and thus requiring another labeling method to assess membrane receptor binding of Cry34Ab1. Since trypsinized Cry3Ba1 had limited activity against western corn rootworm, and thus the bioassay with the corn rootworm using cold iodinated Cry3Ba1 trypsin core was thought difficult to assess the activity change. In addition, the specific binding of ¹²⁵I-Cry3Ba1 to the BBMV was detected even though the level was low. Cold-iodination of Cry3Ba1 and its toxicity assay were ignored. Radiolabeled ¹²⁵I-Cry35Ab1 and ¹²⁵I-Cry3Ba1 were obtained through iodination with Pierce® Iodination Beads (Pierce) and Na¹²⁵I. Zeba™ Desalt Spin Columns (Pierce) were used to remove unincorporated or free Na¹²⁵I from the iodinated protein. The specific radioactivities of the iodinated Cry proteins ranged from 1-5 uCi/ug. Multiple batches of labeling and binding assays were conducted.

Example 11

Saturation Binding Assays

[0103] Specific or saturation binding assays were performed using ¹²⁵I-labeled Cry toxins as described previously (Li et al. 2004b). To determine specific binding and estimate the binding affinity (disassociation constant, Kd) and binding site concentration (Bmax) of Cry35Ab1 and Cry3Ba1 to the insect BBMV, a series of increasing concentrations of either ¹²⁵I-Cry35Ab1 or ¹²⁵I-Cry3Ba1 were incubated with a given concentration (0.1 mg/ml) of the insect BBMV, respectively, in 150 ul of 20 mM Bis-Tris, pH 6.0, 150 mM KCl, supplemented with 0.1% BSA at room temperature for 1 hour with gentle shaking. Toxin bound to BBMV was separated from free toxin in the suspension by centrifugation at 20,000×g at room temperature for 8 min. The pellet was washed twice with (ice-cold) 900 ul of the same buffer containing 0.1% BSA. The radioactivity remaining in the pellet was measured with a COBRAII Auto-Gamma counter (Packard, a Canberra company) and considered total binding. Another series of binding reactions were setup as side by side, and a 500-1,000-fold excess of unlabeled corresponding toxin was included in each of the binding reactions to fully occupy all specific binding sites on the BBMV, which was used to determine non-specific binding. Specific binding was estimated by subtracting the non-specific binding from the total binding. The Kd and Bmax values of these toxins were estimated using the specific binding against the concentrations of the labeled toxin used by running GraphPad Prism 5.01 (GraphPad Software, San Diego, Calif.). The charts were made using either Microsoft Excel or GraphPad Prism software. The experiments were replicated at least four times and the result plotted in the graphs of FIG. 1A (binding of ¹²⁵I-Cry35Ab1 to BBMV) and FIG. 1B (binding of ¹²⁵I-Cry3Ba1 to BBMV). These binding experiments demonstrated that both ¹²⁵I-Cry35Ab1 and ¹²⁵I-Cry3Ba1 were able to specifically bind to the BBMV (FIGS. 1A and 1B). ¹²⁵I-Cry35Ab1 and ¹²⁵I-Cry3Ba1 had a binding affinity Kd=11.66±11.44, 7.35±3.81 (nM), respectively, and a binding site concentration Bmax=0.78±0.46, 0.55±0.13 (pmol/mg BBMV), respectively.

[0104] The specific binding of ¹²⁵I-Cry35Ab1 was carried out at the presence of unlabeled Cry34Ab1 (1:50=¹²⁵I-Cry35Ab1:Cry34Ab1, molar ratio). The binding parameters (Kd and Bmax) were not obtained because the specific binding of ¹²⁵I-Cry35Ab1 was not saturated (FIG. 2). However, the specific binding of ¹²⁵I-Cry35Ab1 accounted for approximately 90% of the total binding at the presence of unlabeled Cry34Ab1.

Example 12

Competition Binding Assays

[0105] Competition binding assays were conducted to determine if Cry34Ab1 and Cry35Ab1 separately, plus their mixture as a binary toxin, share a same set of binding sites with Cry3Ba1. For homologous competition binding assays of Cry3Ba1, increasing amounts (0-2,500 nM) of unlabeled Cry3Ba1 were first mixed with 5 nM ¹²⁵I-Cry3Ba1, and then incubated the insect BBMV at with 0.1 mg/ml at room temperature for 1 hour, respectively, to allow them compete for the putative receptor(s) on the BBMV. Similarly, Cry35Ab1 homologous competition was completed with 5 nM ¹²⁵I-Cry35Ab1 at the absence or presence of unlabeled Cry34Ab1

(1:50=¹²⁵I-Cry35Ab1:Cry34Ab1, molar ratio), and with the BBMV at 0.03 mg/ml, respectively. The percentages of bound ¹²⁵I-Cry3Ba1 or ¹²⁵I-Cry35Ab1 to the BBMV were determined for each of the reactions as compared to the initial total (or specific) binding at absence of unlabeled competitor.

[0106] Heterologous competition binding assays between ¹²⁵I-Cry35Ab1 and unlabeled Cry3Ba1 were conducted at absence or presence of unlabeled Cry34Ab1 to identify if they share a same set of binding site(s). This was achieved by increasing the amount of unlabeled Cry3Ba1 as a competitor to compete for the binding with ¹²⁵I-Cry35Ab1 alone or ¹²⁵I-Cry35Ab1+Cry34Ab1 (1:50=¹²⁵I-Cry35Ab1:Cry34Ab1, molar ratio). Similarly, reciprocal heterologous competition binding assays were also conducted, which was achieved by increasing the amount of unlabeled Cry35Ab1 and Cry34Ab1 separately, or the Cry35Ab1+Cry34Ab1 (1:50=Cry35Ab1:Cry34Ab1, molar ratio) mixture, as one or two competitors included in the reactions to compete for the binding with the labeled Cry3Ba1, respectively. The experiments were replicated at least three times and the result plotted in the graphs of FIG. 3A (percent binding of ¹²⁵I-Cry35Ab alone) and FIG. 3B (percent binding of ¹²⁵I-Cry35Ab1 in the presence of Cry34Ab1).

[0107] The experimental results demonstrated that Cry35Ab1 was able to compete off the specific binding of ¹²⁵I-Cry35Ab1 regardless of absence (FIG. 3A) or presence (FIG. 3B) of Cry34Ab1. However, Cry3Ba1 was unable to compete off the specific binding of ¹²⁵I-Cry35Ab1 at either absence or presence of Cry34Ab1. In reciprocal competition binding assays, Cry3Ba was also able to displace itself over 20% of the total binding, which reflects it completely competed off its specific binding because the specific binding accounts only a small fraction (see FIG. 1B). However, either Cry34Ab1, or Cry35Ab1 alone, or the mixture of Cry35Ab1+

Cry34Ab1 (1:10) was not able to displace ¹²⁵I-Cry3Ba1. These data indicated that Cry35Ab1 alone or mixture of Cry35Ab1+Cry34Ab1 does not share a receptor binding site with Cry3Ba1.

REFERENCES

- [0108]** Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, *Anal. Biochem.* 72, 248-254.
- [0109]** Li, H., Oppert, B., Higgins, R. A., Huang, F., Zhu, K. Y., Buschman, L. L., 2004a. Comparative analysis of proteinase activities of *Bacillus thuringiensis*-resistant and -susceptible *Ostrinia nubilalis* (Lepidoptera: Crambidae). *Insect Biochem. Mol. Biol.* 34, 753-762.
- [0110]** Li, H., Oppert, B., Gonzalez-Cabrera, J., Ferré, J., Higgins, R. A., Buschman, L. L. and Zhu, K. Y. and Huang, F. 2004b. Binding analysis of Cry1Ab and Cry1Ac with membrane vesicles from *Bacillus thuringiensis*-resistant and -susceptible *Ostrinia nubilalis* (Lepidoptera: Crambidae). *Biochem. Biophys. Res. Commun.* 323, 52-57.
- [0111]** Wolfersberger, M. G., Luthy, P., Maurer, A., Parenti, P., Sacchi, F., Giordana, B., Hanozet, G. M., 1987. Preparation and partial characterization of amino acid transporting brush border membrane vesicles from the larval midgut of the cabbage butterfly (*Pieris brassicae*). *Comp. Biochem. Physiol.* 86A, 301-308.
- [0112]** US Patent Application No. 20080193974.2008. BACTERIAL LEADER SEQUENCES FOR INCREASED EXPRESSION
- [0113]** US Patent Application No. 20060008877.2006. Expression systems with sec-system secretion.
- [0114]** US Patent Application No. 20080058262.2008. rPA optimization.

SEQUENCE LISTING

```

<160> NUMBER OF SEQ ID NOS: 5

<210> SEQ ID NO 1
<211> LENGTH: 383
<212> TYPE: PRT
<213> ORGANISM: Bacillus thuringiensis

<400> SEQUENCE: 1

Met Leu Asp Thr Asn Lys Val Tyr Glu Ile Ser Asn His Ala Asn Gly
1             5             10             15

Leu Tyr Ala Ala Thr Tyr Leu Ser Leu Asp Asp Ser Gly Val Ser Leu
20             25             30

Met Asn Lys Asn Asp Asp Asp Ile Asp Asp Tyr Asn Leu Lys Trp Phe
35             40             45

Leu Phe Pro Ile Asp Asp Asp Gln Tyr Ile Ile Thr Ser Tyr Ala Ala
50             55             60

Asn Asn Cys Lys Val Trp Asn Val Asn Asn Asp Lys Ile Asn Val Ser
65             70             75             80

Thr Tyr Ser Ser Thr Asn Ser Ile Gln Lys Trp Gln Ile Lys Ala Asn
85             90             95

Gly Ser Ser Tyr Val Ile Gln Ser Asp Asn Gly Lys Val Leu Thr Ala
100            105            110

```

-continued

Gly	Thr	Gly	Gln	Ala	Leu	Gly	Leu	Ile	Arg	Leu	Thr	Asp	Glu	Ser	Ser
		115					120					125			
Asn	Asn	Pro	Asn	Gln	Gln	Trp	Asn	Leu	Thr	Ser	Val	Gln	Thr	Ile	Gln
		130				135					140				
Leu	Pro	Gln	Lys	Pro	Ile	Ile	Asp	Thr	Lys	Leu	Lys	Asp	Tyr	Pro	Lys
145					150					155					160
Tyr	Ser	Pro	Thr	Gly	Asn	Ile	Asp	Asn	Gly	Thr	Ser	Pro	Gln	Leu	Met
				165					170					175	
Gly	Trp	Thr	Leu	Val	Pro	Cys	Ile	Met	Val	Asn	Asp	Pro	Asn	Ile	Asp
			180					185					190		
Lys	Asn	Thr	Gln	Ile	Lys	Thr	Thr	Pro	Tyr	Tyr	Ile	Leu	Lys	Lys	Tyr
		195					200					205			
Gln	Tyr	Trp	Gln	Arg	Ala	Val	Gly	Ser	Asn	Val	Ala	Leu	Arg	Pro	His
	210					215					220				
Glu	Lys	Lys	Ser	Tyr	Thr	Tyr	Glu	Trp	Gly	Thr	Glu	Ile	Asp	Gln	Lys
225					230					235					240
Thr	Thr	Ile	Ile	Asn	Thr	Leu	Gly	Phe	Gln	Ile	Asn	Ile	Asp	Ser	Gly
				245					250					255	
Met	Lys	Phe	Asp	Ile	Pro	Glu	Val	Gly	Gly	Gly	Thr	Asp	Glu	Ile	Lys
			260					265					270		
Thr	Gln	Leu	Asn	Glu	Glu	Leu	Lys	Ile	Glu	Tyr	Ser	His	Glu	Thr	Lys
		275					280					285			
Ile	Met	Glu	Lys	Tyr	Gln	Glu	Gln	Ser	Glu	Ile	Asp	Asn	Pro	Thr	Asp
	290					295					300				
Gln	Ser	Met	Asn	Ser	Ile	Gly	Phe	Leu	Thr	Ile	Thr	Ser	Leu	Glu	Leu
305					310					315					320
Tyr	Arg	Tyr	Asn	Gly	Ser	Glu	Ile	Arg	Ile	Met	Gln	Ile	Gln	Thr	Ser
			325						330					335	
Asp	Asn	Asp	Thr	Tyr	Asn	Val	Thr	Ser	Tyr	Pro	Asn	His	Gln	Gln	Ala
			340					345					350		
Leu	Leu	Leu	Leu	Thr	Asn	His	Ser	Tyr	Glu	Glu	Val	Glu	Glu	Ile	Thr
		355					360					365			
Asn	Ile	Pro	Lys	Ser	Thr	Leu	Lys	Lys	Leu	Lys	Lys	Tyr	Tyr	Phe	
	370					375					380				

<210> SEQ ID NO 2

<211> LENGTH: 354

<212> TYPE: PRT

<213> ORGANISM: Bacillus thuringiensis

<400> SEQUENCE: 2

Met	Leu	Asp	Thr	Asn	Lys	Val	Tyr	Glu	Ile	Ser	Asn	His	Ala	Asn	Gly
1				5					10					15	
Leu	Tyr	Ala	Ala	Thr	Tyr	Leu	Ser	Leu	Asp	Asp	Ser	Gly	Val	Ser	Leu
		20					25					30			
Met	Asn	Lys	Asn	Asp	Asp	Asp	Ile	Asp	Asp	Tyr	Asn	Leu	Lys	Trp	Phe
	35						40				45				
Leu	Phe	Pro	Ile	Asp	Asp	Asp	Gln	Tyr	Ile	Ile	Thr	Ser	Tyr	Ala	Ala
	50					55					60				
Asn	Asn	Cys	Lys	Val	Trp	Asn	Val	Asn	Asn	Asp	Lys	Ile	Asn	Val	Ser
65				70					75					80	
Thr	Tyr	Ser	Ser	Thr	Asn	Ser	Ile	Gln	Lys	Trp	Gln	Ile	Lys	Ala	Asn
			85					90						95	

-continued

Gly	Ser	Ser	Tyr	Val	Ile	Gln	Ser	Asp	Asn	Gly	Lys	Val	Leu	Thr	Ala
			100					105					110		
Gly	Thr	Gly	Gln	Ala	Leu	Gly	Leu	Ile	Arg	Leu	Thr	Asp	Glu	Ser	Ser
		115					120					125			
Asn	Asn	Pro	Asn	Gln	Gln	Trp	Asn	Leu	Thr	Ser	Val	Gln	Thr	Ile	Gln
		130				135						140			
Leu	Pro	Gln	Lys	Pro	Ile	Ile	Asp	Thr	Lys	Leu	Lys	Asp	Tyr	Pro	Lys
145					150					155					160
Tyr	Ser	Pro	Thr	Gly	Asn	Ile	Asp	Asn	Gly	Thr	Ser	Pro	Gln	Leu	Met
				165					170					175	
Gly	Trp	Thr	Leu	Val	Pro	Cys	Ile	Met	Val	Asn	Asp	Pro	Asn	Ile	Asp
			180					185					190		
Lys	Asn	Thr	Gln	Ile	Lys	Thr	Thr	Pro	Tyr	Tyr	Ile	Leu	Lys	Lys	Tyr
		195					200					205			
Gln	Tyr	Trp	Gln	Arg	Ala	Val	Gly	Ser	Asn	Val	Ala	Leu	Arg	Pro	His
	210						215				220				
Glu	Lys	Lys	Ser	Tyr	Thr	Tyr	Glu	Trp	Gly	Thr	Glu	Ile	Asp	Gln	Lys
225					230					235					240
Thr	Thr	Ile	Ile	Asn	Thr	Leu	Gly	Phe	Gln	Ile	Asn	Ile	Asp	Ser	Gly
				245					250					255	
Met	Lys	Phe	Asp	Ile	Pro	Glu	Val	Gly	Gly	Gly	Thr	Asp	Glu	Ile	Lys
			260					265					270		
Thr	Gln	Leu	Asn	Glu	Glu	Leu	Lys	Ile	Glu	Tyr	Ser	His	Glu	Thr	Lys
		275					280					285			
Ile	Met	Glu	Lys	Tyr	Gln	Glu	Gln	Ser	Glu	Ile	Asp	Asn	Pro	Thr	Asp
	290					295					300				
Gln	Ser	Met	Asn	Ser	Ile	Gly	Phe	Leu	Thr	Ile	Thr	Ser	Leu	Glu	Leu
305					310					315					320
Tyr	Arg	Tyr	Asn	Gly	Ser	Glu	Ile	Arg	Ile	Met	Gln	Ile	Gln	Thr	Ser
			325						330					335	
Asp	Asn	Asp	Thr	Tyr	Asn	Val	Thr	Ser	Tyr	Pro	Asn	His	Gln	Gln	Ala
			340					345					350		

Leu Leu

<210> SEQ ID NO 3
 <211> LENGTH: 659
 <212> TYPE: PRT
 <213> ORGANISM: Bacillus thuringiensis

<400> SEQUENCE: 3

Met	Ile	Arg	Met	Gly	Gly	Arg	Lys	Met	Asn	Pro	Asn	Asn	Arg	Ser	Glu
1				5					10					15	
Tyr	Asp	Thr	Ile	Lys	Val	Thr	Pro	Asn	Ser	Glu	Leu	Pro	Thr	Asn	His
		20						25					30		
Asn	Gln	Tyr	Pro	Leu	Ala	Asp	Asn	Pro	Asn	Ser	Thr	Leu	Glu	Glu	Leu
		35					40					45			
Asn	Tyr	Lys	Glu	Phe	Leu	Arg	Met	Thr	Ala	Asp	Asn	Ser	Thr	Glu	Val
	50					55				60					
Leu	Asp	Ser	Ser	Thr	Val	Lys	Asp	Ala	Val	Gly	Thr	Gly	Ile	Ser	Val
65					70					75				80	
Val	Gly	Gln	Ile	Leu	Gly	Val	Val	Gly	Val	Pro	Phe	Ala	Gly	Ala	Leu
			85					90						95	
Thr	Ser	Phe	Tyr	Gln	Ser	Phe	Leu	Asn	Ala	Ile	Trp	Pro	Ser	Asp	Ala

-continued

100							105					110				
Asp	Pro	Trp	Lys	Ala	Phe	Met	Ala	Gln	Val	Glu	Val	Leu	Ile	Asp	Lys	
		115					120					125				
Lys	Ile	Glu	Glu	Tyr	Ala	Lys	Ser	Lys	Ala	Leu	Ala	Glu	Leu	Gln	Gly	
	130					135					140					
Leu	Gln	Asn	Asn	Phe	Glu	Asp	Tyr	Val	Asn	Ala	Leu	Asp	Ser	Trp	Lys	
145					150					155					160	
Lys	Ala	Pro	Val	Asn	Leu	Arg	Ser	Arg	Arg	Ser	Gln	Asp	Arg	Ile	Arg	
				165					170					175		
Glu	Leu	Phe	Ser	Gln	Ala	Glu	Ser	His	Phe	Arg	Asn	Ser	Met	Pro	Ser	
			180					185					190			
Phe	Ala	Val	Ser	Lys	Phe	Glu	Val	Leu	Phe	Leu	Pro	Thr	Tyr	Ala	Gln	
		195					200					205				
Ala	Ala	Asn	Thr	His	Leu	Leu	Leu	Lys	Asp	Ala	Gln	Val	Phe	Gly		
210					215					220						
Glu	Glu	Trp	Gly	Tyr	Ser	Ser	Glu	Asp	Ile	Ala	Glu	Phe	Tyr	Gln	Arg	
225					230					235					240	
Gln	Leu	Lys	Leu	Thr	Gln	Gln	Tyr	Thr	Asp	His	Cys	Val	Asn	Trp	Tyr	
				245					250					255		
Asn	Val	Gly	Leu	Asn	Ser	Leu	Arg	Gly	Ser	Thr	Tyr	Asp	Ala	Trp	Val	
		260						265					270			
Lys	Phe	Asn	Arg	Phe	Arg	Arg	Glu	Met	Thr	Leu	Thr	Val	Leu	Asp	Leu	
		275					280					285				
Ile	Val	Leu	Phe	Pro	Phe	Tyr	Asp	Val	Arg	Leu	Tyr	Ser	Lys	Gly	Val	
	290					295					300					
Lys	Thr	Glu	Leu	Thr	Arg	Asp	Ile	Phe	Thr	Asp	Pro	Ile	Phe	Thr	Leu	
305					310					315					320	
Asn	Ala	Leu	Gln	Glu	Tyr	Gly	Pro	Thr	Phe	Ser	Ser	Ile	Glu	Asn	Ser	
			325						330					335		
Ile	Arg	Lys	Pro	His	Leu	Phe	Asp	Tyr	Leu	Arg	Gly	Ile	Glu	Phe	His	
		340						345					350			
Thr	Arg	Leu	Arg	Pro	Gly	Tyr	Ser	Gly	Lys	Asp	Ser	Phe	Asn	Tyr	Trp	
		355					360					365				
Ser	Gly	Asn	Tyr	Val	Glu	Thr	Arg	Pro	Ser	Ile	Gly	Ser	Asn	Asp	Thr	
	370					375					380					
Ile	Thr	Ser	Pro	Phe	Tyr	Gly	Asp	Lys	Ser	Ile	Glu	Pro	Ile	Gln	Lys	
385					390					395					400	
Leu	Ser	Phe	Asp	Gly	Gln	Lys	Val	Tyr	Arg	Thr	Ile	Ala	Asn	Thr	Asp	
			405						410					415		
Ile	Ala	Ala	Phe	Pro	Asp	Gly	Lys	Ile	Tyr	Phe	Gly	Val	Thr	Lys	Val	
		420						425					430			
Asp	Phe	Ser	Gln	Tyr	Asp	Asp	Gln	Lys	Asn	Glu	Thr	Ser	Thr	Gln	Thr	
		435					440					445				
Tyr	Asp	Ser	Lys	Arg	Tyr	Asn	Gly	Tyr	Leu	Gly	Ala	Gln	Asp	Ser	Ile	
	450					455					460					
Asp	Gln	Leu	Pro	Pro	Glu	Thr	Thr	Asp	Glu	Pro	Leu	Glu	Lys	Ala	Tyr	
465					470					475					480	
Ser	His	Gln	Leu	Asn	Tyr	Ala	Glu	Cys	Phe	Leu	Met	Gln	Asp	Arg	Arg	
			485						490					495		
Gly	Thr	Ile	Pro	Phe	Phe	Thr	Trp	Thr	His	Arg	Ser	Val	Asp	Phe	Phe	
		500						505					510			

-continued

```

Asn Thr Ile Asp Ala Glu Lys Ile Thr Gln Leu Pro Val Val Lys Ala
  515                      520                      525

Tyr Ala Leu Ser Ser Gly Ala Ser Ile Ile Glu Gly Pro Gly Phe Thr
  530                      535                      540

Gly Gly Asn Leu Leu Phe Leu Lys Glu Ser Ser Asn Ser Ile Ala Lys
  545                      550                      555                      560

Phe Lys Val Thr Leu Asn Ser Ala Ala Leu Leu Gln Arg Tyr Arg Val
  565                      570                      575

Arg Ile Arg Tyr Ala Ser Thr Thr Asn Leu Arg Leu Phe Val Gln Asn
  580                      585                      590

Ser Asn Asn Asp Phe Leu Val Ile Tyr Ile Asn Lys Thr Met Asn Ile
  595                      600                      605

Asp Gly Asp Leu Thr Tyr Gln Thr Phe Asp Phe Ala Thr Ser Asn Ser
  610                      615                      620

Asn Met Gly Phe Ser Gly Asp Thr Asn Asp Phe Ile Ile Gly Ala Glu
  625                      630                      635                      640

Ser Phe Val Ser Asn Glu Lys Ile Tyr Ile Asp Lys Ile Glu Phe Ile
  645                      650                      655

Pro Val Gln

<210> SEQ ID NO 4
<211> LENGTH: 489
<212> TYPE: PRT
<213> ORGANISM: Bacillus thuringiensis

<400> SEQUENCE: 4

Ser Gln Asp Arg Ile Arg Glu Leu Phe Ser Gln Ala Glu Ser His Phe
  1          5          10          15

Arg Asn Ser Met Pro Ser Phe Ala Val Ser Lys Phe Glu Val Leu Phe
  20          25          30

Leu Pro Thr Tyr Ala Gln Ala Ala Asn Thr His Leu Leu Leu Lys
  35          40          45

Asp Ala Gln Val Phe Gly Glu Glu Trp Gly Tyr Ser Ser Glu Asp Ile
  50          55          60

Ala Glu Phe Tyr Gln Arg Gln Leu Lys Leu Thr Gln Gln Tyr Thr Asp
  65          70          75          80

His Cys Val Asn Trp Tyr Asn Val Gly Leu Asn Ser Leu Arg Gly Ser
  85          90          95

Thr Tyr Asp Ala Trp Val Lys Phe Asn Arg Phe Arg Arg Glu Met Thr
  100         105         110

Leu Thr Val Leu Asp Leu Ile Val Leu Phe Pro Phe Tyr Asp Val Arg
  115         120         125

Leu Tyr Ser Lys Gly Val Lys Thr Glu Leu Thr Arg Asp Ile Phe Thr
  130         135         140

Asp Pro Ile Phe Thr Leu Asn Ala Leu Gln Glu Tyr Gly Pro Thr Phe
  145         150         155         160

Ser Ser Ile Glu Asn Ser Ile Arg Lys Pro His Leu Phe Asp Tyr Leu
  165         170         175

Arg Gly Ile Glu Phe His Thr Arg Leu Arg Pro Gly Tyr Ser Gly Lys
  180         185         190

Asp Ser Phe Asn Tyr Trp Ser Gly Asn Tyr Val Glu Thr Arg Pro Ser
  195         200         205

Ile Gly Ser Asn Asp Thr Ile Thr Ser Pro Phe Tyr Gly Asp Lys Ser

```

-continued

210				215				220							
Ile	Glu	Pro	Ile	Gln	Lys	Leu	Ser	Phe	Asp	Gly	Gln	Lys	Val	Tyr	Arg
225				230						235				240	
Thr	Ile	Ala	Asn	Thr	Asp	Ile	Ala	Ala	Phe	Pro	Asp	Gly	Lys	Ile	Tyr
			245						250					255	
Phe	Gly	Val	Thr	Lys	Val	Asp	Phe	Ser	Gln	Tyr	Asp	Asp	Gln	Lys	Asn
			260						265					270	
Glu	Thr	Ser	Thr	Gln	Thr	Tyr	Asp	Ser	Lys	Arg	Tyr	Asn	Gly	Tyr	Leu
			275				280							285	
Gly	Ala	Gln	Asp	Ser	Ile	Asp	Gln	Leu	Pro	Pro	Glu	Thr	Thr	Asp	Glu
			290				295							300	
Pro	Leu	Glu	Lys	Ala	Tyr	Ser	His	Gln	Leu	Asn	Tyr	Ala	Glu	Cys	Phe
305							310				315				320
Leu	Met	Gln	Asp	Arg	Arg	Gly	Thr	Ile	Pro	Phe	Phe	Thr	Trp	Thr	His
			325						330					335	
Arg	Ser	Val	Asp	Phe	Phe	Asn	Thr	Ile	Asp	Ala	Glu	Lys	Ile	Thr	Gln
			340						345					350	
Leu	Pro	Val	Val	Lys	Ala	Tyr	Ala	Leu	Ser	Ser	Gly	Ala	Ser	Ile	Ile
			355				360							365	
Glu	Gly	Pro	Gly	Phe	Thr	Gly	Gly	Asn	Leu	Leu	Phe	Leu	Lys	Glu	Ser
			370				375							380	
Ser	Asn	Ser	Ile	Ala	Lys	Phe	Lys	Val	Thr	Leu	Asn	Ser	Ala	Ala	Leu
385							390				395				400
Leu	Gln	Arg	Tyr	Arg	Val	Arg	Ile	Arg	Tyr	Ala	Ser	Thr	Thr	Asn	Leu
			405						410					415	
Arg	Leu	Phe	Val	Gln	Asn	Ser	Asn	Asn	Asp	Phe	Leu	Val	Ile	Tyr	Ile
			420						425					430	
Asn	Lys	Thr	Met	Asn	Ile	Asp	Gly	Asp	Leu	Thr	Tyr	Gln	Thr	Phe	Asp
			435				440							445	
Phe	Ala	Thr	Ser	Asn	Ser	Asn	Met	Gly	Phe	Ser	Gly	Asp	Thr	Asn	Asp
			450				455							460	
Phe	Ile	Ile	Gly	Ala	Glu	Ser	Phe	Val	Ser	Asn	Glu	Lys	Ile	Tyr	Ile
465							470				475				480
Asp	Lys	Ile	Glu	Phe	Ile	Pro	Val	Gln							
			485												

<210> SEQ ID NO 5

<211> LENGTH: 123

<212> TYPE: PRT

<213> ORGANISM: Bacillus thuringiensis

<400> SEQUENCE: 5

Met	Ser	Ala	Arg	Glu	Val	His	Ile	Asp	Val	Asn	Asn	Lys	Thr	Gly	His
1				5					10					15	
Thr	Leu	Gln	Leu	Glu	Asp	Lys	Thr	Lys	Leu	Asp	Gly	Gly	Arg	Trp	Arg
			20					25					30		
Thr	Ser	Pro	Thr	Asn	Val	Ala	Asn	Asp	Gln	Ile	Lys	Thr	Phe	Val	Ala
		35				40						45			
Glu	Ser	Asn	Gly	Phe	Met	Thr	Gly	Thr	Glu	Gly	Thr	Ile	Tyr	Tyr	Ser
		50				55					60				
Ile	Asn	Gly	Glu	Ala	Glu	Ile	Ser	Leu	Tyr	Phe	Asp	Asn	Pro	Phe	Ala
65					70					75					80
Gly	Ser	Asn	Lys	Tyr	Asp	Gly	His	Ser	Asn	Lys	Ser	Gln	Tyr	Glu	Ile

-continued

85								90				95			
Ile	Thr	Gln	Gly	Gly	Ser	Gly	Asn	Gln	Ser	His	Val	Thr	Tyr	Thr	Ile
100								105				110			
Gln	Thr	Thr	Ser	Ser	Arg	Tyr	Gly	His	Lys	Ser					
115								120							

1. A transgenic plant that produces a Cry34 protein, a Cry35 protein, and a Cry3B insecticidal protein.

2. The transgenic plant of claim 1, said plant further produces a fourth insecticidal protein selected from the group consisting of Cry3A and Cry6A.

3. Seed of a plant according to claim 1, wherein said seed comprises DNA encoding said proteins.

4. A field of plants comprising a plurality of plants according to claim 1.

5. The field of plants of claim 4, said field further comprising non-Bt refuge plants, wherein said refuge plants comprise less than 40% of all crop plants in said field.

6. The field of plants of claim 5, wherein said refuge plants comprise less than 30% of all crop plants in said field.

7. The field of plants of claim 5, wherein said refuge plants comprise less than 20% of all crop plants in said field.

8. The field of plants of claim 5, wherein said refuge plants comprise less than 10% of all crop plants in said field.

9. The field of plants of claim 5, wherein said refuge plants comprise less than 5% of all crop plants in said field.

10. The field of plants of claim 4, wherein said field lacks refuge plants.

11. The field of plants of claim 5, wherein said refuge plants are in blocks or strips.

12. A mixture of seeds comprising refuge seeds from non-Bt refuge plants, and a plurality of seeds of claim 3, wherein said refuge seeds comprise less than 40% of all the seeds in the mixture.

13. The mixture of seeds of claim 12, wherein said refuge seeds comprise less than 30% of all the seeds in the mixture.

14. The mixture of seeds of claim 12, wherein said refuge seeds comprise less than 20% of all the seeds in the mixture.

15. The mixture of seeds of claim 12, wherein said refuge seeds comprise less than 10% of all the seeds in the mixture.

16. The mixture of seeds of claim 12, wherein said refuge seeds comprise less than 5% of all the seeds in the mixture.

17. A seed bag or container comprising a plurality of seeds of claim 3, said bag or container having zero refuge seed.

18. A method of managing development of resistance to a Cry protein by an insect, said method comprising planting seeds to produce a field of plants of claim 4.

19. A field of 4, wherein said plants occupy more than 10 acres.

20. A plant of claim 1, wherein said plant is a maize plant.

21. A plant cell of a plant of claim 1, wherein said Cry35 protein is at least 95% identical with a sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2, said Cry3B insecticidal protein is at least 95% identical with a sequence selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:4, and said Cry34 protein is at least 95% identical with SEQ ID NO:5.

22. A plant of claim 1, wherein said Cry35 protein comprises a sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2, said Cry3B insecticidal protein comprises a sequence selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:4, and said Cry34 protein comprises SEQ ID NO:5.

23. A method of producing the plant cell of claim 21.

24. A method of controlling a rootworm insect by contacting said insect with a Cry34 protein, a Cry35 protein, and a Cry3B insecticidal protein.

25. The plant of claim 1 wherein said Cry34 protein is a Cry34A protein, said Cry35 protein is a Cry35A protein, and said Cry3B protein is a Cry3Ba protein.

26. The plant of claim 1 wherein said Cry34 protein is a Cry34Ab protein and said Cry35 protein is a Cry35Ab protein.

27. The plant of claim 2 wherein said Cry3A protein is a Cry3Aa protein and said Cry6A protein is a Cry6Aa protein.

28. The method of claim 24 wherein said Cry34 protein is a Cry34A protein, said Cry35 protein is a Cry35A protein, and said Cry3B protein is a Cry3Ba protein.

29. The method of claim 24 wherein said Cry34 protein is a Cry34Ab protein and said Cry35 protein is a Cry35Ab protein.

* * * * *